Hair's here for breast cancer
Monday, 12 May, 2008
Sydney biotech Fermiscan has completed a 2000-patient validation trial of its human hair test for breast cancer.
The trial, to compare results from current breast cancer screening methods like mammography and ultrasound - along with subsequent biopsy and pathology results - found that the Fermiscan test achieved 69 per cent accuracy.
The success rate went up to 75 per cent once samples from patients who had chemically treated their hair were excluded.
The test uses x-ray diffraction from synchrotron light to detect an unusual ring shape in the diffraction pattern of hair when a woman has breast cancer.
In a statement, Fermiscan said it will continue progress towards commercialising the test, which it hopes to market through women's health clinics.
For more on Fermiscan, see the May/June issue of ALS.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
